ReviewVaccines2019
Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens.
Review in Vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Establishment and Validation of a Cell-Based Relative Potency Method for Respiratory Syncytial Virus mRNA Vaccine Drug Substance.Vaccines · 2026Article
- RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges.Immunologic research · 2025Review
- Capillary-Based Physicochemical Characterization of Lipid Nanoparticles.Electrophoresis · 2025Article
- Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle.Vaccines · 2025Review
- A novel in-vitro expression assay by LC/MS/MS enables multi-antigen mRNA vaccine characterization.Scientific reports · 2025Article
- Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection.NPJ vaccines · 2025Article
- Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations.Frontiers in immunology · 2025Review
- Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size.Human vaccines & immunotherapeutics · 2024Article
- Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine.Vaccines · 2024Article
- Review
- An antibody-free evaluation of an mRNA COVID-19 vaccine.Biologicals : journal of the International Association of Biological Standardization · 2024Article
- Generation and Characterization of In Vitro Transcribed mRNA.Methods in molecular biology (Clifton, N.J.) · 2024Article
- A convenient analytic method for gel quantification using ImageJ paired with Python or R.PloS one · 2024Article
- mRNA vaccine quality analysis using RNA sequencing.Nature communications · 2023Article
- mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond.European journal of drug metabolism and pharmacokinetics · 2023Review
- Review
- Maximizing mRNA vaccine production with Bayesian optimization.Biotechnology and bioengineering · 2022Article
- Review
- Advances in COVID-19 mRNA vaccine development.Signal transduction and targeted therapy · 2022Review
- Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The preferred product characteristics (for chemistry, control, and manufacture), in addition to safety and efficacy, are quintessential requirements for any successful therapeutic. Messenger RNA vaccines constitute a relatively new alternative to traditional vaccine development platforms, and thus there is less clarity regarding the criteria needed to ensure regulatory compliance and acceptance. Generally, to identify the ideal product characteristics, a series of assays needs to be developed, qualified and ultimately validated to determine the integrity, purity, stability, and reproducibility of a vaccine target. Here, using the available literature, we provide a summary of the array of biophysical and biochemical assays currently used in the field to characterize mRNA vaccine antigen candidates. Moreover, we review various in vitro functional cell-based assays that have been employed to facilitate the early assessment of the biological activity of these molecules, including the predictive immune response triggered in the host cell. Messenger RNA vaccines can be produced rapidly and at large scale, and thus will particularly benefit from well-defined and well-characterized assays ultimately to be used for in-process, release and stability-indications, which will allow equally rapid screening of immunogenicity, efficacy, and safety without the need to conduct often lengthy and costly in vivo experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.